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Purpose: Juvenile polyposis syndrome (JPS) is a rare, autosomal-
dominantly inherited cancer predisposition caused in approxi-
mately 50% of cases by pathogenic germline variants in SMAD4 and
BMPR1A. We aimed to gather detailed clinical and molecular
genetic information on JPS disease expression to provide a basis for
management guidelines and establish open access variant databases.
Methods: We performed a retrospective, questionnaire-based
European multicenter survey on and established a cohort of SMAD4/
BMPR1A pathogenic variant carriers from the medical literature.
Results: We analyzed questionnaire-based data on 221 JPS patients (126
kindreds) from ten European centers and retrieved literature-based
information on 473 patients. Compared with BMPR1A carriers, SMAD4
carriers displayed anemia twice as often (58% vs. 26%), and exclusively
showed overlap symptoms with hemorrhagic telangiectasia (32%) and an
increased prevalence (39% vs. 13%) of gastric juvenile polyps. Cancer,
reported in 15% of JPS patients (median age 41 years), mainly occurred in
the colorectum (overall: 62%, SMAD4: 58%, BMPR1A: 88%) and the
stomach (overall: 21%; SMAD4: 27%, BMPR1A: 0%).
Conclusion: This comprehensive retrospective study on
genotype–phenotype correlations in 694 JPS patients corroborates previous
observations on JPS in general and SMAD4 carriers in particular, facilitates
recommendations for clinical management, and provides the basis for
open access variant SMAD4 and BMPR1A databases.
Genetics inMedicine (2020) 22:1524–1532; https://doi.org/10.1038/s41436-
020-0826-1
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INTRODUCTION
With an estimated incidence of 1:16,000 to 1:100,000, juvenile
polyposis syndrome (JPS; OMIM 174900) represents a rare,
autosomal-dominantly inherited cancer predisposition syn-
drome in which patients develop numerous juvenile type
hamartomatous polyps (JPs) in the gastrointestinal (GI) tract
and are at increased lifetime risk of 9–50% for GI cancers,
mostly of the colon.1–3 The clinical diagnosis is established if
an individual develops synchronously and/or metachronously
five or more colorectal JPs, multiple JPs throughout the GI
tract, or any number of JPs and a family history of juvenile
polyposis.4 JPS is particularly prone to misdiagnosis (e.g.,
small juvenile polyps are often misdiagnosed as inflammatory
polyps because they lack the diagnostic features of juvenile
type polyps) and differentiation from PTEN hamartoma
tumor syndrome (PHTS) can be challenging. Therefore,
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multigene panel diagnostics in patients with clinical suspicion
of PHTS should also include SMAD4 and BMPR1A.
In 45–55% of all JPS patients the clinical diagnosis can be
confirmed by identification of a germline pathogenic variant
(PV) in either the SMAD4 (Locus Reference Genomic [LRG]
ID LRG_318t1) or the BMPR1A (LRG ID LRG_298t1) gene,
with the majority consisting of missense and nonsense
variants, small insertions/deletions, and large genomic dele-
tions.5–7 Both proteins belong to the transforming growth
factor-β (TGF-β)/bone morphogenetic protein (BMP) super-
family of molecules with SMAD4 serving as central mediator
of TGF-β and BMP signaling.8 While SMAD4 loss-of-function
alterations have been associated with tumorigenesis as well as
with a juvenile polyposis–hereditary hemorrhagic telangiecta-
sia overlap syndrome (JPS-HHT; OMIM 1750509), SMAD4
de novo gain-of-function variants result in autosomal-
dominant Myhre syndrome, a connective tissue disorder with
multisystem involvement and intellectual disability (OMIM
13921010). Moreover, microdeletions encompassing both the
BMPR1A and the PTEN gene loci on chromosome 10q22-q23
have been described in patients presenting with early-onset
JPS and features of PTEN hamartoma tumor syndrome, the
severity depending on the extent of the deletion.11 The
pathogenetic events behind SMAD4- and BMPR1A-associated
juvenile polyposis are still poorly understood; only scarce data
are available on the putative roles of these genes as tumor
suppressors and the nature of the respective somatic
alterations (2nd hit) involved in polyp formation.12–15
Despite being known for more than 50 years16 clinical
guidelines for JPS, due to its rarity, still essentially depend on
clinical and genetic information gathered from single series/
center reports, mostly focused on SMAD4 PV carriers, and
expert opinion.17 Additionally, there exists no comprehensive,
open access database on genetic variants in SMAD4 or
BMPR1A. The aims of this retrospective study were to
describe the clinical and molecular genetic features from a
European, multicenter survey on JPS patients, compare them
with literature-derived data on SMAD4/BMPR1A PV carriers,
and provide recommendations for management on the basis
of both new and previously published data. In addition, the
data establish the basis for SMAD4 and BMPR1A Leiden
Open Variant Databases (LOVD).
MATERIALS AND METHODS
European collaborative study (ECS) group
Enrollment and data collection
Ten medical centers from eight European countries partici-
pated in this retrospective, European collaborative study
(ECS) on JPS and contributed patient data in an anonymized
fashion based on a questionnaire that specifically asked for
clinical, familial, and genetic details (Supplementary Table 1
and Supplementary Fig. A). The study was conducted with the
approval of the Ethikkommission beider Basel (“Basler Studie
ueber familiaere Tumorkrankheiten,” number 258/05) and
all collaborating centers had obtained local approval for
the study according to national guidelines, adhering to the
principles set out in the Declaration of Helsinki. Informed
consent was obtained from all patients. Only patients who
fulfilled the clinical criteria for JPS and in whom a disease
causing, i.e., likely pathogenic (class 4) or pathogenic (class 5)
SMAD4 or BMPR1A germline variant could be identified were
submitted. Thirty JPS patients had to be excluded from
the study because of incomplete genetic and/or clinical data.
The final ECS group comprised 221 patients from 126
kindreds (1 to 9 patients per kindred).
Literature-based SMAD4/BMPR1A PV carrier (LBSB) group
Search and selection criteria
To retrieve all published SMAD4/BMPR1A carriers of PVs
reported in the medical literature, a comprehensive search for
entries between 1 January 1998 and 31 December 2018 was
performed using six databases: CINAHL, EMBASE, MED-
LINE/PubMed, PsycINFO, Psyndex, and Web of Science.
Each database was searched individually for genotype and
phenotype characteristics using both free text searches as well
as entry term searches (Supplementary Fig. B). Following
the selection process depicted in Supplementary Fig. C and
exclusion of (1) patients with promoter or unspecified
SMAD4/BMPR1A variants, (2) patients with SMAD4-
associated Myhre syndrome (n= 8), and (3) ECS group
patients having already been published (n= 39), 628 SMAD4/
BMPR1A variant carriers could be retrieved. Applying variant
classification criteria based on the American College of
Medical Genetics and Genomics (ACMG) standards and
guidelines18 a total of 473 patients (249 SMAD4, 224
BMPR1A) carrying pathogenic (i.e., class 4 and 5) gene
variants were included, and phenotype data, as for the ECS
group, were gathered, where available, from the pertinent
publications for comparison.
Categorization of polyp numbers reported
Information on polyp numbers was summarized in three
categories: “few,” “multiple,” and “massive.” “Few” encom-
passes descriptions such as “few,” “some,” or 1–4 polyps;
“multiple” such as “multiple,” “numerous,” “several,” “many,”
or 5–99 polyps; and “massive” containing “massive,” “diffuse,”
“carpeted,” “lots,” or ≥100 polyps.
Statistical methods
Statistical comparison of patients’ features, encompassing
phenotypic characteristics and molecular status, was done
using Chi-square and Fisher’s exact tests for categorical
variables (e.g., gender, presence of symptoms), or Student’s t
test for continuous variables (e.g., age at diagnosis), with all of
the probabilities reported as two-tailed P values, considering
p < 0.05 to be statistically significant. All calculations were
done either in Microsoft Excel 2016 or Stat View v.4.5
(Abacus Concepts).
RESULTS
The 221 ECS patients (sex ratio: m:f= 105:116) from 126
kindreds consisted of 127 patients with a germline PV in the
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SMAD4 gene (57.5%; 71 kindreds; 56 nonindex) and 94
patients with a PV in the BMPR1A gene (42.5%; 55 kindreds;
39 nonindex). Having excluded previously published ECS
patients, the LBSB group consisted of 473 patients (224
BMPR1A; 249 SMAD4) with individual phenotypic informa-
tion ascertained from 232 (49.1%) PV carriers (sex ratio [n=
160]: m:f= 80:80).
Age at diagnosis
The median age at JPS diagnosis of all ECS patients was 25.0
years (interquartile range [IQR] 28.0, range 0.2–86 years)
with a similar age at diagnosis for SMAD4 (28.0 years) and
BMPR1A (24.5 years) PV carriers (Supplementary Table 2).
A significant difference in age at diagnosis was seen between
index patients (19.5 years; IQR 23.5, range 0.6–86 years)
compared with other family members, referred to as
nonindex patients (32.0 years; IQR 30.5, range 0.2–76
years; p= 0.0017).
While median age at JPS diagnosis was similar for LBSB
patients in general (23.0 years, IQR 27.0; n= 104) and for
SMAD4 carriers (26.0 years, IQR 26.5; n= 71), carriers of
large cytogenetic alterations, i.e., microdeletions at 10q23
encompassing the BMPR1A and PTEN gene loci, displayed a
significantly younger age (1.5 years, IQR 2.6; n= 8) compared
with carriers of other BMPR1A pathogenic variants (23.0
years, IQR 26.0; n= 26; p < 0.001). This was also observed in
the five ECS index patients with 10q23 microdeletions whose
median age at diagnosis was 6.0 years (IQR 5.0) compared
with carriers of other types of BMPR1A variants (21.0 years;
IQR 19.0; n= 48; p= 0.009).
Symptoms at presentation
The most common symptoms reported in ECS index patients
were rectal bleeding (43%) and anemia (47%). Whereas the
former was nearly equally frequent in SMAD4 (41%) and
BMPR1A (46%) PV carriers, anemia was reported twice as
often in SMAD4 carriers (58% vs. 26%, p= 0.0003; Table 1),
who also exhibited symptoms of hereditary hemorrhagic
telangiectasia in 32% (13/41). In ECS nonindex patients, these
symptoms were significantly less common in SMAD4 (14%;
11%; p= 0.006) and absent in BMPR1A PV carriers (0% for
both; p < 0.0001). Symptoms associated with JPS-HHT, such
as epistaxis, telangiectasia, or other types of arteriovenous
malformations, were exclusively reported in SMAD4 PV
carriers (24%, 21%, and 14% of index patients, respectively)
but not in BMPR1A PV carriers (0%). A similar pattern was
observed in LBSB patients (SMAD4 [n= 55]: 16.1%, 10.8%,
and 12.6%; BMPR1A: 0%).
Congenital heart defects (CHD), mainly ventricular and
atrial septal defects, were reported in 3 (4.2%) SMAD4 and
5 (9.1%) BMPR1A index patients (p= 0.29; Table 1). Overall,
CHD was more frequently stated in BMPR1A compared with
Table 1 Symptoms at presentation.
Index patients Nonindex patients
Totala Total with featureb Totala Total with featureb
n n (%
of total)
Median age
(years)c (IQR)
n n (%
of total)
Median age
(years)c (IQR)
Intestinal Blood in stool 126 54 (42.9%) 11.5 (15.0) 95 8 (8.4%) 17.0 (21.5)
SMAD4 71 29 (40.8%) 11.0 (13.0) 56 8 (14.3%) 17.0 (21.5)
BMPR1A 55 25 (45.5%) 12.0 (17.3) 39 0 -
Anemia 126 55 (46.7%) 17.5 (26.0) 95 6 (6.3%) 35.5 (11.0)
SMAD4 71 41 (57.7%) 18.0 (27.5) 56 6 (10.7%) 35.5 (11.0)
BMPR1A 55 14 (25.5%) 15.0 (30.8) 39 0 -
Extraintestinal,
vascular
Epistaxis 126 17 (13.5%) 11.0 (31.0) 95 8 (8.4%) 23.0 (33.8)
SMAD4 71 17 (23.9%) 11.0 (31.0) 56 8 (14.3%) 23.0 (33.8)
BMPR1A 55 0 39 0 -
Telangiectasia 126 15 (11.9%) 38.0 (18.5) 95 2 (2.1%) 32.5 (33.0)
SMAD4 71 15 (21.1%) 38.0 (18.5) 56 2 (3.6%) 32.5 (33.0)
BMPR1A 55 0 39 0 -
AVM 126 10 (7.9%) 46.5 (12.0) 95 3 (3.2%) 31.0 (14.0)
SMAD4 71 10 (14.1%) 46.5 (12.0) 56 3 (5.4%) 31.0 (14.0)
BMPR1A 55 0 39 0 -
Cardiac Congenital heart
defects
126 8 (6.3%) 6.0 (12.0) 95 3 (3.2%) 1.0 (0.0)
SMAD4 71 3 (4.2%) 23 (0.0) 56 0 -
BMPR1A 55 5 (9.1%) 4.5 (14.0) 39 3 (7.7%) 1.0 (0.0)
AVM arteriovenous malformation, IQR interquartile range.
aTotal number of patients.
bTotal number of index or nonindex patients who presented with the respective symptom.
cDue to missing age at diagnosis the calculation of the median age is often based on fewer than the total number of patients with the respective feature.
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SMAD4 PV carriers (8.5% [8/94] vs. 2.4% [3/127]; p= 0.06),
which was also the case in the LBSB group (4.0% [9/224] vs.
0.4% [1/249]; p= 0.008). The small numbers precluded any
meaningful statistical/genotype–phenotype analysis; we did
not, however, observe an overrepresentation of a specific type
of PV or protein domain affected. Aortic aneurysms were
exclusively reported in SMAD4 PV carriers (ECS group: 2
[1.6%], LBSB group: 1 [0.4%]).
Few ECS and LBSB patients displayed other symptoms such
as macrocephaly (n= 11, with 9 of them carrying a 10q32
microdeletion encompassing the BMPR1A and PTEN gene
loci), failure to thrive (n= 9), and protein-losing enteropathy
(5). Except for a LBSB group patient with a 10q32
microdeletion, no further cases of cleft palate or polydactyly
were reported.
Polyp occurrence in the GI tract
Juvenile polyps in the colorectum
A high prevalence of juvenile polyps (JPs) in the colon was
reported in ECS index patients (BMPR1A: 91% and SMAD4:
86%), essentially mirrored by the LBSB group (96% [42/44] and
93% [69/74]), whereas this was significantly less frequently the
case for ECS nonindex patients (41% and 52%, respectively;
p < 0.0001; Table 2). JPs were more frequently reported in the
proximal than the distal colon, both in index (40/70; 57.1%)
and clinically affected nonindex (13/19; 68.4%) patients
(Table 3). The load of colonic JPs was similar in both groups,
ECS and LBSB, as well as in the gene-specific subgroups, with
most index patients presenting with multiple (5 to 99) JPs
(Table 3). In the ECS group, median age at diagnosis was
similar for index and nonindex patients (18.0 years and 20.0
years). Interestingly, BMPR1A index and nonindex patients
displayed a similar median age at diagnosis, compared with
SMAD4 carriers where nonindex patients were diagnosed
about 11.5 years later. Unfortunately, for most LBSB patients
specific information regarding age at diagnosis and polyp
occurrence could not be retrieved from the respective
publications, which precluded meaningful calculations in the
corresponding LBSB subgroups.
Compared with those in the colon, rectal JPs in the ECS
group overall were significantly less frequently reported
(70.6% [n= 156] vs. 31.7% [n= 70]; p < 0.01) and appeared
to be somewhat more prevalent in BMPR1A index patients
(Table 2). In nonindex patients median age at diagnosis of
rectal JP was lower (13.0 years) compared with colonic JP
(20.0 years, p= 0.15; Table 4). Rectal polyp load was similar
among BMPR1A and SMAD4 PV carriers, with the majority
of patients presenting with few (<5) to multiple (5 to 100) JPs
(Table 3).
Juvenile polyps in the stomach and in the small bowel
As specific information regarding the presence of JP in the
upper GI tract is largely missing in the LBSB patients, we
only report the findings in the ECS patients. A clear
genotype–phenotype correlation was observed for gastric
juvenile polyposis, which was significantly more frequent in
SMAD4 than BMPR1A PV carriers, both in index and
nonindex patients (SMAD4 39% and 38% vs. BMPR1A 13%
and 5%; p= 0.001 and 0.0002, respectively; Table 2). JP
formation in the stomach was also more severe in SMAD4
Table 2 Polyp occurrence in the GI tract.
Index patients Nonindex patients
Totala Total with featureb Totala Total with featureb
n n (% of total) Median age (years)c (IQR) n n (% of total) Median age (years)c (IQR)
JP in stomach 126 35 (27.8%) 40.0 (16.0) 95 23 (24.2%) 42.0 (19.0)
SMAD4 71 28 (39.4%) 40.0 (13.5) 56 21 (37.5%) 41.0 (14.8)
BMPR1A 55 7 (12.7%) 35.5 (28.0) 39 2 (5.1%) 56.5 (11.0)
JP in small intestine 126 13 (10.3%) 24.0 (26.5) 95 10 (10.5%) 46.0 (22.5)
SMAD4 71 10 (14.1%) 29.0 (18.5) 56 10 (17.9%) 46.0 (22.5)
BMPR1A 55 3 (5.5%) 14.0 (30.0) 39 0
JP in colon 126 111 (88.1%) 18.0 (25.0) 95 45 (47.4%) 20.0 (30.8)
SMAD4 71 61 (85.9%) 19.0 (24.5) 56 29 (51.8%) 30.5 (35.0)
BMPR1A 55 50 (90.9%) 18.0 (23.3) 39 16 (41%) 16.0 (31.0)
JP in rectum 126 58 (46.0%) 18.5 (28.0) 95 12 (12.6%) 13.0 (15.0)
SMAD4 71 30 (42.3%) 14.0 (28.8) 56 7 (12.5%) 6.0 (11.8)
BMPR1A 55 28 (50.9%) 19.0 (27.8) 39 5 (12.8%) 15.0 (22.0)
Other types of polypsd 126 58 (46.0%) 23.0 (23.0) 95 25 (26.3%) 40.0 (29.0)
SMAD4 71 30 (42.3%) 23.0 (24.0) 56 16 (28.6%) 42.0 (25.0)
BMPR1A 55 28 (50.9%) 23.0 (20.5) 39 9 (23.1%) 31.0 (41.0)
GI gastrointestinal, IQR interquartile range, JP juvenile polyp.
aTotal number of patients.
bTotal number of index or nonindex patients who presented with the respective symptom.
cDue to missing age at diagnosis the calculation of the median age is often based on fewer than the total number of patients with the respective feature.
dAdenomas, serrated and other polyps.
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pathogenic variant carriers since most BMPR1A PV carriers
(86%) presented with only few (<5) polyps, whereas most
SMAD4 PV carriers (71%) presented with multiple JPs or
even a massive (≥100) number of JPs (17%; p= 0.0001;
Table 3). Combining the data from index and nonindex
patients, who displayed similar JP loads, the difference
remained statistically significant (p= 0.0002). JP formation
in the small intestine was also more often reported in SMAD4
(15.7%) than BMPR1A PV carriers (3.2%; Table 2).
Age at diagnosis of JP in the GI tract
The median age at JP diagnosis in the different sections of the GI
tract did not significantly differ between ECS-SMAD4 and ECS-
BMPR1A PV carriers. A significant difference was only observed
for index patients with stomach polyps where the reported
median age at diagnosis was roughly 20 years later (40.0 years)
compared with colonic (18.0 years; p < 0.0001; Table 2).
Other polyps
In 37.6% of ECS and 82.2% of LBSB patients other types of
polyps were reported, mostly adenomas and hyperplastic
polyps, with similar frequencies in SMAD4 and BMPR1A PV
carriers (ECS: 36.2% and 39.4%; LBSB: 72.7% and 96.6%,
respectively; Table 2).
Cancer occurrence
Cancer was reported in 15.4% (34/221) of ECS patients
(index patients: 15.1% [19/126]; nonindex patients: 15.8%
[15/95], and 11.0% [52/473] of LBSB patients; Table 4). In
most ECS patients (78.1%, 25/32) the cancer diagnosis was
either accompanied or preceded by the diagnosis of colonic
JPs. A notable exception was found in three ECS-SMAD4
pathogenic variant carriers, two index and one nonindex,
who presented with cancer and JPs in the stomach/small
intestine, but none in the colorectum; instead of JPs, two of
them were reported to have multiple colorectal adenomas
or hyperplastic polyps. The overall median age at cancer
diagnosis was 41 years, which is 23 years later compared
with the diagnosis of colon JPs (18.5 years, p < 0.0001) and
similar to that of gastric JP (40 years). Overall, cancer was
significantly more frequently observed in ECS-SMAD4
(20.5%, n= 26) compared with ECS-BMPR1A PV carriers
Table 3 Number of juvenile polyps according to GI tract site.
Index patients Nonindex patients
Total SMAD4 BMPR1A Total SMAD4 BMPR1A
Stomach 31 24 7 17 15 2
Few 9 3 (13%) 6 (86%) 7 5 (33%) 2 (100%)
Multiple 18 17 (71%) 1 (14%) 6 6 (40%) 0
Massive 4 4 (17%) 0 4 4 (27%) 0
Small intestine 10 7 3 9 9 0
Few 6 5 (71%) 1 (33%) 5 5 (56%) 0 (%)
Multiple 4 2 (29%) 2 (67%) 4 4 (44%) 0 (%)
Massive 0 0 0 0 0 0
Colon 92 49 43 37 23 14
Few 11 7 (14%) 4 (9%) 9 5 (22%) 4 (29%)
Multiple 69 33 (68%) 36 (84%) 27 17 (74%) 10 (71%)
Massive 12 9 (18%) 3 (7%) 1 1 (4%) 0
Proximal colon 40 25 15 13 8 5
Few 7 5 (20%) 2 (13%) 7 5 (63%) 2 (40%)
Multiple 32 19 (76%) 13 (87%) 6 3 (37%) 3 (60%)
Massive 1 1 (4%) 0 0 0 0
Distal colon 30 20 10 6 3 3
Few 14 9 (45%) 5 (45%) 2 0 2 (67%)
Multiple 15 10 (50%) 5 (55%) 4 3 (100%) 1 (33%)
Massive 1 1 (5%) 0 0 0 0
Rectum 38 20 18 8 3 5
Few 16 11 (50%) 5 (28%) 6 3 (100%) 3 (60%)
Multiple 22 9 (50%) 13 (72%) 2 0 2 (40%)
Massive 0 0 0 0 0 0
Other polyps 48 25 23 16 12 4
Few 15 5 (20%) 10 (43%) 8 5 (42%) 3 (75%)
Multiple 29 18 (72%) 11 (48%) 8 7 (58%) 1 (25%)
Massive 4 2 (8%) 2 (9%) 0 0 0
GI gastrointestinal.
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(8.5%; n= 8; p= 0.015), which could be attributed to the
difference in cancer occurrence among nonindex patients
(23% vs. 5%, respectively; p= 0.022).
Colorectal cancer (n= 21; median age at diagnosis: 38
years; range 19–67 years) was reported in 11.8% (15/127) of
ECS-SMAD4 and 7.4% (7/94) of ECS-BMPR1A carriers
(Table 4). It accounted for 61.8% (21/34) of all cancers
reported, representing 57.7% (15/26) of all SMAD4 and 87.5%
(7/8) of all BMPR1A cancers. Eighty percent (12/15) of
SMAD4 variants were nonsense/frameshift type compared
with 28.6% (2/7) in BMPR1A carriers (p= 0.052). Gastric
cancer (n= 7; all SMAD4; median age at diagnosis: 44 years;
range 38–55 years) was reported in SMAD4 carriers only
(5.5%; 7/127) and accounted for 20.6% (7/34) of all cancers
reported and for 26.9% (7/26) of all SMAD4 tumors. Similar
observations were made in the LBSB group where colorectal
and gastric cancer accounted for 63% (n= 12) and 15.8%
(n= 3; all SMAD4) of the cancer burden. Few other cancers
reported in the ECS group were located in the small intestine
(n= 1), thyroid (n= 2), lung (n= 1), and cancer of unknown
origin (n= 1).
Six (2.7%) ECS patients were reported to have developed
metachronous cancers (Table 4). In three of them both
cancers had occurred in the GI tract (three colorectal, three
gastric, and one cancer of the small intestine), whereas three,
each with colorectal cancer, had additionally developed lung,
pancreatic, and thyroid cancer, respectively.
Pathogenic variant type frequencies
Overall, frameshift, nonsense, and missense variants
accounted for the majority of pathogenic SMAD4 (72.9%)
and BMPR1A (61.8%) alterations in the ECS as well as the
LBSB group (SMAD4: 79.9%; BMPR1A: 70.8%; Supplemen-
tary Table 3). Only large genomic, i.e., single or multiexon
deletions in SMAD4 were significantly overrepresented in the
ECS compared with the LBSB group (21.4% vs. 6.8%; p=
0.003). De novo variant occurrence was suspected in 10 (7.9%;
8 SMAD4, 2 BMPR1A) of 126 ECS index patients as well as in
26 (5.5%; 11 SMAD4, 15 BMPR1A) of 473 LBSB pathogenic
variant carriers.
As detailed above, statistically significant genotype–phenotype
correlations were identified with regard to younger age at
diagnosis in carriers of 10q23 microdeletions encompassing the
BMPR1A and PTEN loci. Interestingly, with regard to juvenile
polyposis of infancy, the three index patients, aged between
7 months and 2 years at diagnosis, all carried BMPR1A PVs;
only one, however, carried the 10q23 microdeletion while the
other two harbored an exon 1 deletion and a splice site
alteration (c.430+2T>C), respectively. In SMAD4 PV carriers a
more severe gastric phenotype as well as an HHT overlap
phenotype were observed. In addition, index patients with
SMAD4 missense PVs (n= 14) displayed a significantly
younger median age at diagnosis (10.5 years, IQR 22.0)
compared with those with SMAD4 frameshift changes (28.0
years, IQR 31.0, n= 29; p= 0.028); this finding, however, was
not present among nonindex patients (missense: 36 years, IQR
12.8; frameshift: 29 years, IQR 30.0; p= 0.39). Even when
combining the ECS and LBSB data sets no further statistically
significant phenotypic differences with regard to the type of
genetic variant or protein domain affected could be identified.
We assume that this is partly due to the comparatively small
numbers in the respective variant subgroups and partly to the
pronounced phenotypic heterogeneity in JPS. The latter was
particularly striking in carriers of identical germline variants
(e.g., 19 patients from 9 unrelated families carrying the
c.1244_1247del SMAD4 variant). Moreover, marked intrafami-
lial phenotypic heterogeneity, in particular regarding JP and
cancer occurrence, was evident in four (1 SMAD4, 3 BMPR1A)
Table 4 Cancer occurrence in JPS patients.
Index patients Nonindex patients
Totala Total with featureb Totala Total with featureb
n n (% of total) Median age (years)c (IQR) n n (% of total) Median age (years)c (IQR)
Cancer 126 19 (15.1%) 37.5 (14.0) 95 15 (15.8%) 45.0 (14.0)
SMAD4 71 13 (18.3%) 42.0 (16.3) 56 13 (23.2%) 43.0 (13.0)
BMPR1A 55 6 (10.9%) 34.0 (6.3) 39 2 (5.1%) 55.0 (10.0)
Colorectal cancer 126 11 (8.7%) 36.0 (7.5) 95 10 (11.6%) 49.0 (15.5)
SMAD4 71 6 (8.5%) 39.0 (13.0) 56 9 (16.1%) 46.5 (14.0)
BMPR1A 55 5 (9.1%) 35.0 (9.0) 39 2 (5.1%) 55.0 (10)
Gastric cancer 126 4 (3.2%) 44.0 (12.5) 95 3 (3.2%) 42.0 (12.8)
SMAD4 71 4 (5.6%) 44.0 (12.5) 56 3 (5.4%) 42.0 (12.8)
BMPR1A 55 0 39 0
Multiple cancers 126 4 (3.2%) 95 2 (2.1%)
SMAD4 71 3 (4.2%) 56 2 (3.6%)
BMPR1A 55 1 (1.8%) 39 0
IQR interquartile range, JPS juvenile polyposis syndrome.
aTotal number of patients.
bTotal number of index or nonindex patients who presented with the respective symptom.
cDue to missing age at diagnosis the calculation of the median age is often based on fewer than the total number of patients with the respective feature.
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ECS families with data available on five to ten family members
(data not shown).
DISCUSSION
This large comprehensive retrospective study on genotype–
phenotype correlations in JPS corroborates previous observa-
tions that SMAD4 carrier status is associated with HHT,
multiple gastric JPs, and gastric cancer occurrence; provides
recommendations for management on the basis of both new
and previously published data (Table 5); and establishes the
basis for open access SMAD4 and BMPR1A Leiden Open
Variant Database–powered variant databases.19
The reported age at diagnosis of JPS was similar for both
SMAD4 and BMPR1A pathogenic variant carriers (median 28
and 25 years, respectively). The youngest index patients
reported, both in the ECS and the LBSB group (median age
1.5 and 6 years, respectively), consisted of carriers of large
cytogenetic alterations at 10q23, e.g., microdeletions encom-
passing the BMPR1A and PTEN loci.
As expected, JPS-HHT symptoms in both the ECS and LBSB
group were exclusively reported in SMAD4 but not in BMPR1A
pathogenic variant carriers. In addition, anemia was twice as
often observed in SMAD4 carriers with 32% displaying the
hemorrhagic telangiectasia overlap syndrome (HHT) pheno-
type (p= 0.0006). Unfortunately, the true incidence of HHT/
JPS overlap in those with a SMAD4 PV cannot be established,
as not all SMAD4 carriers underwent systematic screening for
HHT. However, given that almost one third had features of
HHT in this cohort, in addition to past publications suggesting
very high (around 90%) prevalence of JPS/HHT overlap in
SMAD4 carriers,9 we recommend that all patients with a
SMAD4 PV undergo routine screening for HHT, such as a one-
off thoracic computed tomography (CT) scan to screen for
pulmonary arteriovenous malformations and contrast echo-
cardiogram for aortopathy. Surveillance guidelines are not
uniform across countries, and thus referring such patients to a
local HHT specialist center would be advised (European
centers can be identified at https://vascern.eu/expertise/rare-
diseases-wgs/hht-wg/).
While JPs of the colon were twice as frequently reported in
ECS index patients compared with affected family members,
rectal JPs were significantly less frequent than colonic ones
(32% vs. 72%; p < 0.01), independent of the gene affected.
The prevalence and number of gastric JPs, however, were
significantly increased in both SMAD4 index and nonindex
patients, and occurred roughly 20 years later compared with
the colonic JPs (40 vs. 18 years; p < 0.0001). Upper GI
endoscopy surveillance is recommended for patients with JPS.
The data presented here are sufficient, when combined with
published data, to support that upper GI surveillance should
be tailored to the underlying genotype. It would be reasonable
to recommend upper GI surveillance to start at age 18 years
for SMAD4 carriers, with intervals ranging from 1 to 3 years
depending on the number of polyps (Table 5). However,
although approximately 18% of BMPR1A carriers develop
gastric polyps, they are usually smaller and gastric cancer has
not been reported. In view of these findings, starting
surveillance in this group by the age of 25 years and a
surveillance interval of 3 years seems reasonable until further
data are available.
Among the 11% to 15% of LBSB and ECS patients with
cancer, colorectal cancer accounted for 58% (SMAD4) and
88% (BMPR1A) of all cancers reported and occurred about
20 years later (median age 41 years) compared with the age at
diagnosis of colonic JPs (18.5 years; p < 0.0001). Most
patients’ colorectal disease is likely to be manageable
endoscopically. Recent pediatric guidelines produced on
behalf of the European Society for Paediatric Gastroenterol-
ogy Hepatology and Nutrition (ESPHGAN) outline an
approach to colorectal surveillance, commencing at age
12–15 with surveillance interval being personalized according
to the individual’s phenotype.20 However, some patients
will require surgical intervention for either endoscopically
unmanageable disease, or the development of cancer. Where
surgery is being contemplated, it should be personalized
according to the individual’s phenotype. Usually in the
prophylactic setting, a (sub)total colectomy will be the
procedure of choice, retaining the rectum, avoiding the need
for pelvic dissection.
As with the prevalence of gastric JPs, gastric cancer (median
age 44 years) was exclusively reported in SMAD4 PV carriers,
accounting for 27% of SMAD4 tumors. These observations
were essentially mirrored by the LBSB group. It is likely that
gastric cancer occurrence in SMAD4 carriers is under-
estimated since seven ECS patients with massive JP burden
had prophylactic gastric resection/gastrectomy at a median
Table 5 Surveillance recommendations in juvenile polyposis.
Organ Patients Methods Age at starting Interval
Colon, Rectum All JPS patients Colonoscopy 12–15 years 1–3 years
Depending on phenotype
Stomach, Duodenum SMAD4 Gastroduodenoscopy 18 years 1–3 years
Depending on phenotype
BMPR1A 25 years 3 years
Vascular manifestations SMAD4 Referral to HHT specialist
Individual screening
HHT hereditary hemorrhagic telangiectasia, JPS juvenile polyposis syndrome.
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age of 49.5 years. Thus, more of these patients might have
developed gastric cancer. It is difficult on the basis of current
evidence to give firm recommendations regarding gastrect-
omy in SMAD4 carriers. There are no data regarding
outcomes from endoscopic polypectomy in the stomach.
Decisions will need to be made on a case-by-case basis. Those
with advanced gastric polyposis are best seen in a center
experienced in managing this condition. It is likely that the
gastric polyps have a relatively indolent progression. How-
ever, in those with advanced polyposis in whom dysplasia is
found, and in those whose stomachs cannot be adequately/
safely surveyed, a discussion through a specialist multi-
disciplinary team is required and then the option of
prophylactic/risk-reducing surgery should be discussed with
the patient. As always, in the setting of prophylactic, risk-
reducing surgery, retaining the best possible quality of life is
essential and therefore this surgery should be reserved to
highly specialized centers.
In this study small intestine polyps were reported in 15.7%
(20/127) of SMAD4 carriers and 3.2% (3/94) of BMPR1A
carriers. It should be noted that we did not distinguish
duodenal from ileal/jejunal polyps and it is likely that
duodenal polyps predominate here.21 In addition, given that
small bowel surveillance is not routinely recommended, the
true incidence of small bowel polyps cannot be established.
However, these data do support the recommendation that the
small bowel should undergo evaluation for patients who
develop symptoms or unexplained anemia, e.g., with video-
capsule endoscopy (VCE), to look for underlying small bowel
polyps and angioectasia.
The limitations of this study obviously include its retro-
spective nature and, inevitably when dealing with such a rare
disorder, the possibility of ascertainment and/or selection
bias. In addition, differences in patient data collection as well
as completeness of medical records among the participating
centers will impact on data quality and comparability.
Furthermore, certain of the reported phenotypic features
likely represent underestimations since a particular trait may
go unnoticed if not specifically searched for, e.g., arteriove-
nous malformations in SMAD4-associated JPS-HHT, as
reported by O’Malley et al.9
To circumvent these issues clearly, prospective, multicenter-
based studies, as exemplified by the Prospective Lynch
Syndrome Database (PLSD), are needed,22 which could also
inform the outcomes of surveillance measures taken.23
Furthermore, with the novel genetic high-throughput sequen-
cing tools available, the roughly 50% of JPS patients and
families in whom no SMAD4 or BMPR1A alteration can be
identified constitute an obvious target for candidate gene
analysis.
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